FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION +----------------------------------+------------------------------------------+ |(a) Identity of the party to the |ASTRAZENECA PLC | |offer making the disclosure: | | +----------------------------------+------------------------------------------+ |(b) Owner or controller of |N/A | |interests and short positions | | |disclosed, if different from | | |1(a): The naming of nominee or| | |vehicle companies is insufficient | | +----------------------------------+------------------------------------------+ |(c) Name of offeror/offeree in |ASTRAZENECA PLC (OFFEREE) | |relation to whose relevant | | |securities this form relates: | | |Use a separate form for each party| | |to the offer | | +----------------------------------+------------------------------------------+ |(d) Is the party to the offer |OFFEREE | |making the disclosure the offeror | | |or the offeree? | | +----------------------------------+------------------------------------------+ |(e) Date position held: |12 MAY 2014 | +----------------------------------+------------------------------------------+ |(f) Has the party previously |YES: PFIZER INC. (OFFEROR)DISCLOSING TODAY| |disclosed, or is it today | | |disclosing, under the Code in | | |respect of any other party to this| | |offer? | | +----------------------------------+------------------------------------------+ 2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates +------------------------------------------------+---------+-+---------------+-+ |Class of relevant security: | | | | | +------------------------------------------------+---------+-+---------------+-+ | |Interests| |Short positions| | +------------------------------------------------+---------+-+---------------+-+ | |Number |%|Number |%| +------------------------------------------------+---------+-+---------------+-+ |(1) Relevant securities owned and/or controlled:|Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ |(2) Derivatives (other than options): |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ |(3) Options and agreements to purchase/sell: |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ | TOTAL: |Nil |0|Nil |0| +------------------------------------------------+---------+-+---------------+-+ All interests and all short positions should be disclosed. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL). (b) Rights to subscribe for new securities +---------------------------------------------------------------------------+--- -+ |Class of relevant security in relation to which subscription right exists: |None| +---------------------------------------------------------------------------+--- -+ |Details, including nature of the rights concerned and relevant percentages:|None| +---------------------------------------------------------------------------+--- -+ If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (c) Irrevocable commitments and letters of intent +-----------------------------------------------------------------------------+ |Details of any irrevocable commitments or letters of intent procured by the | |party to the offer making the disclosure or any person acting in concert with| |it (see Note 3 on Rule 2.11 of the Code): | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ 3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE +---------------------------------------------------------------------------+ |Details of any interests, short positions and rights to subscribe of any | |person acting in concert with the party to the offer making the disclosure:| +---------------------------------------------------------------------------+ 3(a) Shares held by directors of AstraZeneca PLC +-----------+-----------+--------------------------------------------+ |Director |Number of |Percentage of total issued share capital (%)| | |AstraZeneca| | | |Shares | | +-----------+-----------+--------------------------------------------+ |Pascal |151,581 |0.01200826 | |Soriot | | | +-----------+-----------+--------------------------------------------+ |Marc |500 |0.00003961 | |Dunoyer | | | +-----------+-----------+--------------------------------------------+ |Leif |33,009 |0.002614976 | |Johansson | | | +-----------+-----------+--------------------------------------------+ |Genevieve |1,790 |0.000141804 | |Berger | | | +-----------+-----------+--------------------------------------------+ |Bruce |2,249 |0.000178166 | |Burlington | | | +-----------+-----------+--------------------------------------------+ |Ann Cairns |1,225 |0.000097044 | +-----------+-----------+--------------------------------------------+ |Graham |1,900 |0.000150518 | |Chipchase | | | +-----------+-----------+--------------------------------------------+ |Jean |2,635 |0.000208745 | |-Philippe | | | |Courtois | | | +-----------+-----------+--------------------------------------------+ |Rudy |2,452 |0.000194248 | |Markham | | | +-----------+-----------+--------------------------------------------+ |Nancy |2,643 |0.000209379 | |Rothwell | | | +-----------+-----------+--------------------------------------------+ |Shriti |3,000 |0.00023766 | |Vadera | | | +-----------+-----------+--------------------------------------------+ |John Varley|9,500 |0.000752591 | +-----------+-----------+--------------------------------------------+ |Marcus |63,646 |0.005042042 | |Wallenberg | | | +-----------+-----------+--------------------------------------------+ 3(b) Directors’ interests in awards of AstraZeneca PLC shares under AstraZeneca PLC’s share plans Deferred Bonus Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |3,799 |25/02/2013 |2939 |25/02/2016 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |15,966 |28/03/2014 |3904 |28/03/2017 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |2,679 |28/03/2014 |3904 |28/03/2017 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ Performance Share Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |125,113 |11/06/2013 |3297 |11/06/2016 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |124,066 |28/03/2014 |3904 |28/03/2017 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |90,853 |01/08/2013 |3302 |01/08/2016 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |52,254 |28/03/2014 |3904 |28/03/2017 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ AstraZeneca Investment Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |89,960 |11/06/2013 |3297 |01/01/2021 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,677 |28/03/2014 |3904 |01/01/2022 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |8,176 |01/08/2013 |3302 |01/01/2021 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |8,709 |28/03/2014 |3904 |01/01/2022 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ Restricted Share Award +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,732 |26/10/2012 |2894 |01/10/2014 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ |Pascal |20,732 |26/10/2012 |2894 |01/10/2015 | |Soriot | | | | | +--------+-----------+-------------+-------------------+------------+ Restricted Share Plan +--------+-----------+-------------+-------------------+------------+ |Director|Number of |Date of grant|Award price (pence)|Vesting date| | |AstraZeneca| | | | | |Shares | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |9,103 |01/08/2013 |3302 |15/06/2014 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |41,472 |01/08/2013 |3302 |15/06/2015 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ |Marc |14,930 |01/08/2013 |3302 |01/08/2016 | |Dunoyer | | | | | +--------+-----------+-------------+-------------------+------------+ 3(c) Interests of connected advisers Goldman, Sachs & Co Class of relevant security: USD 0.25 ordinary and ADRs Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 15,066 0.00 222,448 0.01 (2) Derivatives (other than options): 0 0.00 0 0.00 (3) Options and agreements to purchase/sell: 205,600 0.02 177,900 0.01 TOTAL: 220,666 0.02 400,348 0.03 Morgan Stanley B.V. Class of relevant USD 0.25 ordinary and ADRs security: Interests Short positions Number % Number % (1) Relevant securities 0 0.00 0 0.00 owned and/or controlled: (2) Derivatives (other 0 0.00 0 0.00 than options): (3) Options and 6,883 0.00 0 0.00 agreements to purchase/sell: TOTAL: 6,883 0.0005 0 0.00 3(d) Interests of employment benefit trusts +--------------------+-----------+----------------------------------------+ |Entity |Number of |Percentage of existing issued shares (%)| | |AstraZeneca| | | |Shares | | +--------------------+-----------+----------------------------------------+ |AstraZeneca Employee|1,051,810 |0.083324481 | |Share Trust Limited | | | +--------------------+-----------+----------------------------------------+ |AstraZeneca Share |100 |0.000007922 | |Trust Limited | | | +--------------------+-----------+----------------------------------------+ If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL). 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements +-----------------------------------------------------------------------------+ |Details of any indemnity or option arrangement, or any agreement or | |understanding, formal or informal, relating to relevant securities which may | |be an inducement to deal or refrain from dealing entered into by the party to| |the offer making the disclosure or any person acting in concert with it:If | |there are no such agreements, arrangements or understandings, state “none” | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ (b) Agreements, arrangements or understandings relating to options or derivatives +-----------------------------------------------------------------------------+ |Details of any agreement, arrangement or understanding, formal or informal, | |between the party to the offer making the disclosure, or any person acting in| |concert with it, and any other person relating to:(i) the voting rights of | |any relevant securities under any option; or (ii) the voting rights or future| |acquisition or disposal of any relevant securities to which any derivative is| |referenced:If there are no such agreements, arrangements or understandings, | |state “none” | +-----------------------------------------------------------------------------+ |None | +-----------------------------------------------------------------------------+ (c) Attachments Are any Supplemental Forms attached? +------------------------------------+---+ |Supplemental Form 8 (Open Positions)|YES| +------------------------------------+---+ |Supplemental Form 8 (SBL) |NO | +------------------------------------+---+ +-------------------+------------------------------+ |Date of disclosure:|12 May 2014 | +-------------------+------------------------------+ |Contact name: |Adrian Kemp, Company Secretary| +-------------------+------------------------------+ |Telephone number: |020 7604 8000 | +-------------------+------------------------------+ Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. SUPPLEMENTAL FORM 8(OPEN POSITIONS) DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO PURCHASE OR SELL ETC. Note 5(i) on Rule 8 of the Takeover Code (the “Code”) 1. KEY INFORMATION Identity of the person whose open GOLDMAN, SACHS & CO. positions are being disclosed: Name of offeror/offeree in relation to ASTRAZENECA PLC (OFFEREE) whose relevant securities disclosure relates: 2. OPTIONS AND DERIVATIVES Class of Product Written Number of Exercise Typee.g. Expiry relevant description or securities to price American, date security e.g. purchased which per European call option option or unit etc. derivative relates USD 0.25 Call Option Sold 100 75.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Sold 200 45.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 200 75.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 200 80.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 300 72.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 500 80.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 600 60.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 600 67.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 600 70.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Sold 800 67.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Sold 1,000 90.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,100 65.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Sold 1,100 70.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,200 72.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Sold 1,300 62.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 1,300 67.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 1,600 65.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 1,600 67.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,700 62.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 1,800 70.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 1,800 75.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,000 55.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 2,000 70.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,400 77.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 2,600 67.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,700 57.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 2,800 65.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Purchased 2,800 72.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Call Option Purchased 2,900 77.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Sold 3,100 60.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Call Option Purchased 3,100 75.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 3,300 75.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 3,300 85.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 3,500 72.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 4,600 65.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Purchased 5,400 75.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 7,100 72.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Call Option Sold 7,400 70.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 9,400 80.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Purchased 11,100 65.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 18,100 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Call Option Sold 21,900 70.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Sold 32,500 80.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Call Option Purchased 33,300 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 100 35.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 100 40.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 100 40.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 100 47.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 200 30.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 200 37.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 300 60.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 300 70.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 300 75.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 500 52.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 600 57.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 600 65.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 800 67.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 900 27.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 900 32.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 900 70.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 55.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 60.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Purchased 1,000 60.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 1,000 75.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 1,100 70.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Sold 1,200 67.5000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 1,200 72.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Sold 1,300 40.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 2,100 30.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 2,100 50.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 2,100 65.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 2,300 52.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 2,400 35.0000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Purchased 2,600 57.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 2,600 65.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 3,100 67.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 3,600 70.0000 AMER 18/10/2 ordinary USD 014 USD 0.25 Put Option Sold 3,900 52.5000 AMER 15/01/2 ordinary USD 016 USD 0.25 Put Option Sold 4,100 70.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 4,300 60.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 4,700 42.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,000 25.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,100 47.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,200 45.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Purchased 5,900 62.5000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 5,900 62.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Purchased 6,400 50.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 7,100 65.0000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Purchased 7,500 60.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 7,600 67.5000 AMER 21/06/2 ordinary USD 014 USD 0.25 Put Option Sold 8,400 65.0000 AMER 17/05/2 ordinary USD 014 USD 0.25 Put Option Purchased 8,600 55.0000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 10,000 55.0000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 10,400 62.5000 AMER 17/01/2 ordinary USD 015 USD 0.25 Put Option Sold 11,600 57.5000 AMER 19/07/2 ordinary USD 014 USD 0.25 Put Option Sold 16,300 62.5000 AMER 21/06/2 ordinary USD 014 3. AGREEMENTS TO PURCHASE OR SELL Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets The currency of all pieces and other monetary amounts should be stated. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. SUPPLEMENTAL FORM 8 (OPEN POSITIONS) DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC. Note 5(i) on Rule 8 of the Takeover Code (the “Code”) 1. KEY INFORMATION +--------------------------------------------+-------------------------+ |Identity of person whose open positions are |MORGAN STANLEY B.V. | |being disclosed: | | +--------------------------------------------+-------------------------+ |Name of offeror/offeree in relation to whose|ASTRAZENECA PLC (OFFEREE)| |relevant securities the disclosure relates: | | +--------------------------------------------+-------------------------+ 2. OPTIONS AND DERIVATIVES +--------+-----------+---------+-------------+---------+-------------+-------+ |Class of|Product |Written |Number of |Exercise |Typee.g. |Expiry | |relevant|description|or |securities to|price per|American, |date | |security|e.g. |purchased|which |unit |European etc.| | | |call option| |option or | | | | | | | |derivative | | | | | | | |relates | | | | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |1,737 |SEK 336.9|European |26/11/2| |ordinary| | | | | |015 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |610 |SEK 307.4|European |23/11/2| |ordinary| | | | | |017 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |1,956 |SEK 301.9|European |11/5/20| |ordinary| | | | | |16 | +--------+-----------+---------+-------------+---------+-------------+-------+ |USD 0.25|Call option|Written |2,580 |SEK 307.9|European |23/10/2| |ordinary| | | | | |017 | +--------+-----------+---------+-------------+---------+-------------+-------+ 3. AGREEMENTS TO PURCHASE OR SELL ETC. +---------------------------------------------------------------------------+ |Full details should be given so that the nature of the interest or position| |can be fully understood: | +---------------------------------------------------------------------------+ | | +---------------------------------------------------------------------------+ It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences (“CFDs”) or spread bets. The currency of all prices and other monetary amounts should be stated. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Form 8 (OPD) AstraZeneca PLC FORM 8 (OPD) PUBLIC OPENING
Top 10 Most Recent News Articles
SoLo Alpha: Transforming Retail Investment Returns
Pushing Beyond Traditional Financial Constructs In a world where the average Joe is often left holding the short end of the investment stick, SoLo Funds comes charging through with SoLo Alpha, touting a whopping 16% annualized return. They're riding a wave of what seems like a financial revolution, serving up high returns usually reserved for the big fish. It’s hard not...
Continue Reading
Mark Isham: Recognizing the Voice Behind Award Nomination
What's in a Name? Mark Isham Earns His Spotlight Hollywood’s buzz these days has less to do with the usual blockbuster glitter and more with a singular name cresting the scene: Mark Isham. You may not see his name in lights, and yet it’s blaring behind every soundtrack that brings a film to life. This time around, he's in the spotlight not for composing an...
Continue Reading
Olight's Oclip 2: Illuminating the Auto World at SEMA
The Oclip 2 Series: A Game-Changer for Mechanics When Olight sets up shop at the SEMA Show 2026, they're not just pulling a rabbit out of the hat. Nope, they're rolling out the Oclip 2 Series, a lighting tool engineered for those insane angles and shadowy corners under a mechanic's hood. If the idea of a flexible, hands-free light that finally adapts to the fiddly demands...
Continue Reading
FCM Travel Names New CPO to Lead AI Innovation
Fresh Face at the Helm Hiring Mark McSpadden as Chief Product Officer is a move by FCM Travel that signals the company's intent to deepen its roots in tech and innovation within the corporate travel sector. There's no subtlety here—FCM's making a bold statement, and they're throwing serious weight behind their tech strategy. Don’t take this lightly; this is them...
Continue Reading
Shopping Center Sale in NJ: A $41 Million Power Play
A Strategic Move for Bronstein Properties Today in real estate, partners are reshuffling and money's trading hands as RJ Brunelli & Co. puts another feather in its cap. Securing the sale of The Gardens—a 210,845-square-foot power center situated in Morris County's Flanders, N.J.—for a neat $41 million. It wasn't merely about changing hands; it represented a...
Continue Reading
Randi Baptiste Sets a New Standard in Youth Sports
Youth Sports: Revolutionized by Randi Baptiste In an era where youth sports face a minefield of health risks and performance pressures, Randi Baptiste stands out. This isn't just about running around the park—this is about fundamentally transforming how we think about athletic development for young folks. Recognizing Baptiste for his contributions, The Inner Circle...
Continue Reading
Palestinian Doctor's Death Sparks Urgent Calls for Action
When the world loses a healer like Dr. Rizk Abu Shaaira to an airstrike, it feels like we're spiraling further into a pit where humanity becomes collateral damage. Dr. Shaaira, a prominent Palestinian surgeon, found his life brutally cut short amid violence that's becoming as depressingly routine as my morning coffee—a routine nobody asked for. The Unforgiving Reality...
Continue Reading
MY DR NOW Challenges 9-to-5 with New Clinics
Revolutionizing Healthcare Access Latte in one hand and the other hand tapping your steering wheel, trying to squeeze in that elusive doctor’s appointment between work meetings. Sound familiar? Well, those days might just be numbered. MY DR NOW is shaking up the traditional 9-to-5 doctor’s office stereotype by opening two new clinics that’ll stand sentinel seven...
Continue Reading
University of Phoenix Tackles Data: New Degree Insight
Giving Traditional Business Schools a Run for Their Money It's about time someone ditches that outdated case study method and starts teaching folks how to really harness data. Enter the University of Phoenix's new Bachelor of Science in Business Analytics. It's designed with working adults in mind. Wherever you are, this ain't your everyday degree program. It's an online...
Continue Reading
MGS Extends Engagement for BECI Power Line Project
The power game isn't always about flipping switches, my friends. With Midcontinent Grid Solutions (MGS), we're seeing another round of crowd-pleasing playacting as they pump the brakes on the BECI Project. New timeline, new promises—same old story. Investors, environmentalists, and citizens alike are watching this one unfold with a glass of iced tea and crossed fingers....
Continue ReadingTop 5 Most Recently Viewed Articles
Baylin Technologies Secures Major Orders for Antenna Solutions
Baylin Technologies Gains Momentum with New Orders Baylin Technologies Inc. (NASDAQ: BYLTF), a prominent player in wireless technology, has achieved a significant milestone with recent orders amounting to approximately $500,000 CAD. These orders, deriving from their Galtronics subsidiary, will facilitate the installation of antennas across 200 sites in a major...
Continue Reading
Edible Oil Market Trends: Insights and Growth Forecast Ahead
Understanding the Global Edible Oil Market The edible oil market is an essential sector that plays a significant role in the global food industry. With a growing emphasis on health and sustainability, the demand for various types of edible oils has expanded remarkably. Insights from the latest market research indicate that this market is projected to grow significantly,...
Continue Reading
Zapata AI Partners with MAG Aerospace for Advanced Surveillance
Zapata AI Partners with MAG Aerospace for Surveillance Innovations Zapata AI, a pioneering name in generative artificial intelligence solutions, has formed an exciting partnership with MAG Aerospace, aimed at developing a state-of-the-art airborne surveillance platform. This collaboration marks a significant milestone as it blends advanced technology with defense...
Continue Reading
Silvaco's CEO to Speak at Upcoming Tech Summit in Chicago
Silvaco's CEO to Showcase Innovations at Jefferies Summit In an exciting development for the tech industry, Dr. Babak Taheri, the CEO of Silvaco Group, Inc. (Nasdaq: SVCO), will attend the prestigious Jefferies’ Semis, IT Hardware & Comm Tech Summit in Chicago. This summit, recognized for its focus on semiconductors and technology hardware, is set to be held in late...
Continue Reading
Creative Vision for the Spectacular Asian Winter Games Opening
Excitement Builds for the 9th Asian Winter Games As the countdown begins, anticipation is mounting for the opening ceremony of the 9th Asian Winter Games (AWG), set to take place in Harbin, famously known as the "Ice Capital" of China. This event promises an inspiring showcase that draws participants and spectators alike into the magic of winter sports and cultural...
Continue Reading